2:27 PM
 | 
Nov 09, 2017
 |  BC Extra  |  Clinical News

Sage rebounds on Phase III PPD readout

Sage Therapeutics Inc. (NASDAQ:SAGE) jumped $33.99 (54%) to $96.65 Thursday after reporting that brexanolone (formerly SAGE-547) met the primary endpoint in a pair of Phase III trials to treat postpartum depression. Next year, the company plans to submit an NDA to FDA for the positive allosteric modulator (PAM) of GABA A receptor to treat PPD.

The 202B and 202C trials evaluated IV brexanolone in 122 patients with severe PPD and 104 patients with moderate PPD,...

Read the full 355 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >